Contact ROKIT Healthcare:     Email:     Phone: +82-1899-7296     WhatsApp: +82-10-3912-5410 (Da-Yae Lee)

ROKIT Healthcare’s vision for bioprinting:

Bioprinting is not only a revolution that’s underway for the way we create and use model systems for answering basic biological questions; it is revolutionary in the way we practice medicine – instead of using systems that rely on treatments of the symptoms using small molecules or monotherapies, bioprinting shifts focus towards harnessing the body’s own healing potential inherent in the stem cells and 3D human tissue-like microenvironments

Events of November 2020

Bioprinting, with its automated handling, processing and scalability of technology, has made recent advances in creating 3D cancer and microenvironment models with improved results in novel drug testing and development.

In this web mini-symposium, learn from speakers at the front lines of cancer research and bioprinting applications about

  • Key morphology and functional differences between 2D and 3D-organized tumor tissues.
  • Case studies in tumor tissue and microenvironment modeling & cancer therapy developments.
  • Case studies in identifying appropriate biomarkers for early detection and prognosis of cancer.
Register Here

What is 4D Bioprinting?

4D bioprinting is an additive manufacturing process in which cells, biopolymers and growth factors are combined to create living structures that imitate native human tissues. Because these printed tissues are often further incubated to proliferate, mature and change over time, there is a dimension of time here that makes it 4D instead of 3D. The technology brings key values of automation, biomimetic architecture, and on-demand biomanufacturing and is widely applicable to the fields of bioengineering and medicine, from in vitro applications in novel product screening, disease modeling, and animal alternative methods of experiment to in vivo applications in tissue transplantation and regeneration.

Bioprinting Components

The 4D bioprinting technology consists of largely three components: biomaterials, the bioprinter, and design.

  • Biomaterials are bio-compatible and bio-degradable materials that may be derived both from natural and synthetic sources. Naturally-derived biomaterials include collagen, gelatin, elastin, chitin coming from the extracellular matrix of human or animal cells; they can be alginate, sericin, or cellulose coming from seaweed, insects and plants, respectively. Synthetic biomaterials are biodegradable polymers with enough strength and elasticity to apply to human tissues and may have FDA approval as medical device components, i.e. PCL, PLA and PLGA. Natural and synthetic materials can be used in combination to bolster certain mechanical or biochemical properties.
  • Bioprinter is the actual hardware that prints tissue structures based on 3D models. There are various methods of bioprinting today, from inkjet based, laser-assisted and stereolithography methods, but extrusion is the most common one used (over 70%). Key functions of the bioprinter are a built-in clean-chamber and bioreactor that could provide UV disinfection, HEPA filer and mammalian cell culture environments to optimize cell viability and functionality during and after the printing process.
  • Design refers to the 3D models that the bioprinter would create. Models may be obtained either from manual drawings using a design software or may be derived from CAD/MRI scans of a patient body. These 3D model files then get processed with a slicing software into G-CODE, a standard machine language that will dictate how a 3D printer should print the job in a given three-dimensional space.

Bioprinting Process

The process principally involves five key steps:

  • Preparation involves designing the experiment with a clear identification of the problem to address. It includes selection of the right biomaterials, cell types, and 3D models that the printer will use.
  • Bioprinting is the actual printing process. 3D models are sliced into appropriate printing instructions. Bioink is placed in a printer cartridge and deposition takes place based on the digital model.
  • Post-bioprinting is the mechanical and chemical stimulation of printed parts so as to create stable and functional structures for the biological material.
  • Evaluation is the step in which cultured printed tissues are assessed for structural, morphological and functional characterization in comparison with the living tissue standards.
  • Application involves making use of the bioprinted products for various purposes, such as disease modeling, in vitro safety and efficacy testing, and in vivo tissue transplantation.

Future Outlook

Bioprinting is not only a revolution that’s underway for the way we create and use model systems for answering basic biological questions. It’s also a revolution in the way we practice medicine. Instead of using conventional systems that rely on treatments of the symptoms using small molecules or biologics, bioprinting shifts focus toward harnessing the body’s own healing potential inherent in the stem cells. It enables endogenous tissue regeneration by priming the body’s stem cells with the bioprinted “niche”, consisting of growth factors, biomaterials, and three-dimensional architecture.

In the world of aging populations, the ability to create tissues on demand and offer novel regenerative medicine approaches will be crucial in improving the quality of life.

Who is ROKIT Healthcare?

ROKIT Healthcare (ROKIT) is a global healthcare company pioneering in offering the safest and most effective autologous organ regeneration platforms using its proprietary 4D bioprinting technologies across all types of applicable age-related diseases.

ROKIT’s patented technologies are the results of a convergence of know-how’s in the fields of autologous regenerative therapies, biomedical engineering, and healthcare chain innovations. The DFU skin and cartilage regeneration platforms have both received confirmation by the European Medicine Agency (EMA) as non-ATMPs, reducing lead time to market and clinical usage. ROKIT has completed the U.S. FDA registrations for the key components of its organ regeneration platform technologies, including the 4D bioprinting systems named Dr. INVIVO®.

4D Bioprinting Technology Open School Event, Korea

Harvard Medical School, Boston, USA

University of Michigan-Dearborn, USA

AAPS 2019 PharmSci 360 Tech Challenge, USA

ROKIT Healthcare Partners Day Event, Korea

University of Technology, Sydney, Australia

Politecnico di Torino, Italy

Universidad Autónoma de Bucaramanga, Colombia

Trusted by Global User Institutions:

Amore Pacific
Newcastle U
Politecnico di Torino

What is Dr. INVIVO?

Dr. INVIVO® is the 4D bioprinting platform manufactured by ROKIT Healthcare. It is known for introducing some of the world’s first built-in revolutions to bioprinter devices, including:

  • Clean-bench system including disinfection and filtered air flow capabilities (i.e. UV and HEPA H14)
  • Bioreactor capable of maintaining optimal temperature, CO2 and humidity levels for mammalian cell culture
  • FDA registrations for translations to clinical applications

Currently, Dr. INVIVO® portfolio principally includes Dr. INVIVO 4D2 and Dr. INVIVO 4D6. The portfolio is continuing to expand to offer tissue-specific or purpose-specific applications and tools.

Dr. INVIVO 4D Technology

BioPrinting Case Studies

The 4D bioprinting is widely applicable to the fields of bioengineering and medicine. It has in vitro applications in novel product screening, disease modeling, and animal alternative methods of experimentation. It has in vivo applications in tissue transplantation and regeneration. For example, ROKIT Healthcare users have used 4D bioprinting to develop:

Case Studies Overview

Case Studies Overview



Publication Notes

Publication Notes

Clinical Application Spotlight

ROKIT Healthcare partners with global hospital and research institutions to translate the bioprinting technology from the bench to the bedside, making a difference in patients’ lives with regenerative approaches to chronic age-related diseases. Notably, ROKIT’s in-clinic autologous solution for diabetic foot ulcers (DFU) using the bioprinted dermal patch has been validated for safety and efficacy through global clinical studies. The portfolio of cutting-edge organ regeneration platform technologies is continuing to expand to cartilage and kidney regeneration.

Diabetic Foot Ulcers Skin Regeneration

Diabetic Foot Ulcers Skin Regeneration

Cartilage and Kidney Regeneration

Cartilage and Kidney Regeneration

R&D Application Spotlight

ROKIT Healthcare is dedicated to offering the highest quality tools and services tailored to purpose-specific applications of 4D bioprinting across disciplines.

ROKIT Healthcare provides the following tools, as some examples of the constantly growing portfolio:

  • HumaTein for 3D cell culturing with human cell-derived ECM
  • Dr. INVIVO BioPoly for biomaterial development
  • Dr. INVIVO Pharma for pharmaceutical research
  • Dr. INVIVO Derma for in-vitro skin testing
  • Yoli-Lab for customized food research (in partnership with Korea’s food printing specialist company Yolilo)

3D Cell Culturing

3D Cell Culturing

Biomaterial Development
(Dr. INVIVO BioPoly)

Biomaterial Development
(Dr. INVIVO BioPoly)

Pharmaceutical Research
(Dr. INVIVO Pharm)

Pharmaceutical Research
(Dr. INVIVO Pharm)

ROKIT Healthcare in the News

Discover the latest ROKIT articles from the team.


ROKIT Healthcare advances audience access to bioprinting with bioprinting exhibitions and workshops

ROKIT Healthcare is hosting a series of educational workshops for students, teachers, and professionals to teach and highlight the fundamentals of bioprinting and its applications in healthcare. Previous workshops were…


ROKIT Healthcare develops novel cartilage regeneration therapies using bioprinting

ROKIT Healthcare, in cooperation with a Massachusetts-based U.S. hospital, has completed pre-clinical studies for cartilage regeneration using the 3D bioprinting technology and is in the process of clinical studies with…


ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device

ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S. Since 2019, the company has…

Community Pages

Be a part of ROKIT Healthcare’s journey in revolutionizing research and medicine in the new era of organ regeneration. You can stay updated with ROKIT Healthcare’s latest events, webinars, conference attendance, and R&D progress through the following community pages.


LinkedIn LinkedIn


Youtube Youtube


Facebook Facebook